Synapse - Pamela Drullinsky

Results (92)

Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
Blood (2014)

Fulltext@MSK | Save

Ofatumumab-bendamustine as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk adapted design with comprehensive geriatric assessment

Meeting Abstract

Casulo, C.; Iannotta, A.; Walkley, J.; Moskowitz, C. H.; Moskowitz, A. J.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.
Blood (2014)

Fulltext@MSK | Save

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer

Journal Article

Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
Clinical Breast Cancer (2014)

Fulltext@MSK | Save

Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)

Meeting Abstract

Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Final results of phase I/II trial of vorinostat in combination with cyclophosphamide, etoposide, prednisone, and rituximab (R-CVEP) for elderly patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Straus, D. J.; Hamlin, P. A.; Matasar, M. J.; Palomba, M. L.; Drullinsky, P.; Zelenetz, A. D.; Gerecitano, J. F.; Noy, A.; Hamilton, A. M.; Wegner, B.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer

Meeting Abstract

Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
Cancer Research (2012)

Fulltext@MSK | Save

Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer

Meeting Abstract

Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
Cancer Research (2012)

Fulltext@MSK | Save

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease

Journal Article

Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
Leukemia and Lymphoma (2012)

Fulltext@MSK | Save

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer